ThermoGenesis Corp. Gets China FDA Approval For "Cord Blood Separation Device" JQY2301651 From The Beijing Polyongchang Medical Technology Co., Ltd.; Registration Certificate #: National Weapons Injection 20143105298 On 2023-12-08
Portfolio Pulse from Benzinga Newsdesk
ThermoGenesis Corp. has received approval from the China FDA for its 'Cord Blood Separation Device' JQY2301651, manufactured by Beijing Polyongchang Medical Technology Co., Ltd. The device's registration certificate number is National Weapons Injection 20143105298, and the approval was granted on December 8, 2023.
December 14, 2023 | 2:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ThermoGenesis Corp. has received regulatory approval from the China FDA for its cord blood separation device, which could lead to increased market presence and potential revenue growth in China.
The approval of ThermoGenesis Corp.'s cord blood separation device by the China FDA is a significant regulatory milestone that can lead to increased sales and market penetration in China. This news is likely to be viewed positively by investors, as it opens up a large market for the company's product, potentially leading to increased revenue and profitability in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100